JWM
AXSM icon

Janiczek Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Janiczek Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$97.6K Hold
1,213
– – 0.02% 281
2024
Q1 		$96.8K Buy
+1,213
New +$102K 0.02% 294

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janiczek Wealth Management's AXSM Position: Q2 2024 in Review

Janiczek Wealth Management held its Axsome Therapeutics (AXSM) position steady in Q2 2024 at 1,213 shares worth $97.6K. The position accounts for 0.02% of the portfolio, ranked #281.

Janiczek Wealth Management first reported a position in AXSM in Q1 2024 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold AXSM as of Q2 2024.

  • Janiczek Wealth Management held 1,213 shares of Axsome Therapeutics worth $97.6K as of Q2 2024.
  • Janiczek Wealth Management left its Axsome Therapeutics share count unchanged in Q2 2024.
  • Axsome Therapeutics made up 0.02% of Janiczek Wealth Management's portfolio in Q2 2024, its #281 holding.
  • Janiczek Wealth Management first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.